[go: up one dir, main page]

WO2006017627A3 - Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance - Google Patents

Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance Download PDF

Info

Publication number
WO2006017627A3
WO2006017627A3 PCT/US2005/027668 US2005027668W WO2006017627A3 WO 2006017627 A3 WO2006017627 A3 WO 2006017627A3 US 2005027668 W US2005027668 W US 2005027668W WO 2006017627 A3 WO2006017627 A3 WO 2006017627A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
insulin resistance
treating insulin
dietary compositions
docosahexaenoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/027668
Other languages
French (fr)
Other versions
WO2006017627A2 (en
Inventor
Barry Sears
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2006017627A2 publication Critical patent/WO2006017627A2/en
Publication of WO2006017627A3 publication Critical patent/WO2006017627A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention relates to formulations of nutritional supplements, and methods for administering those supplements to alter an insulin level, to treat insulin resistance, and/or to treat obesity in a patient in need thereof. The nutritional supplement includes (a) docosahexaenoic acid (DHA), (b) eicosapentaenoic acid (EPA), and (c) optionally, a specific inhibitor of enzyme delta-5 desaturase (D5D).
PCT/US2005/027668 2004-08-06 2005-08-04 Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance Ceased WO2006017627A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59979304P 2004-08-06 2004-08-06
US60/599,793 2004-08-06

Publications (2)

Publication Number Publication Date
WO2006017627A2 WO2006017627A2 (en) 2006-02-16
WO2006017627A3 true WO2006017627A3 (en) 2006-04-27

Family

ID=35447951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027668 Ceased WO2006017627A2 (en) 2004-08-06 2005-08-04 Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance

Country Status (1)

Country Link
WO (1) WO2006017627A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066915B2 (en) 2006-10-03 2015-06-30 Michael D. Myers Meal replacement compositions and weight control method
US9138415B2 (en) 2009-04-29 2015-09-22 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ597193A (en) 2009-06-15 2014-01-31 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
ES2554657T3 (en) 2009-09-23 2015-12-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy derivative of a statin and methods of use thereof
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
NZ737380A (en) 2012-06-29 2019-05-31 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
RU2020125675A (en) * 2012-06-29 2020-09-16 Амарин Фармасьютикалз Айрлэнд Лимитед METHODS FOR TREATMENT OF PEDIATRIC METABOLIC SYNDROME
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US11109607B2 (en) 2013-11-18 2021-09-07 Gary Hall Oil-based compositions for enhancing oral health and general wellness in humans
JP2017515884A (en) * 2014-03-13 2017-06-15 バリー ディー． シアーズ， Compositions and methods for reducing low levels of chronic inflammation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CA2990140A1 (en) * 2015-06-26 2016-12-29 Pronova Biopharma Norge As Composition for treatment of nafld
CA2995249A1 (en) * 2015-08-14 2017-02-23 Barry D. Sears Materials and methods for modulation of insulin resistance and gut-derived hormones using composite food products
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3251516A1 (en) * 2016-05-30 2017-12-06 Instituto Nacional de Medicina Genomica (INMEGEN) Nutritional composition
EP3251667A1 (en) * 2016-05-30 2017-12-06 Instituto Nacional de Medicina Genomica (INMEGEN) Nutritional composition
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN111991386A (en) 2018-09-24 2020-11-27 阿马里纳药物爱尔兰有限公司 Method of reducing the risk of a cardiovascular event in a subject
CN116350616A (en) 2019-11-12 2023-06-30 阿马里纳药物爱尔兰有限公司 Method for reducing the risk of cardiovascular events in subjects with atrial fibrillation and/or atrial flutter
KR20240012390A (en) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 How to Reduce Your Risk of Heart Failure

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302481A2 (en) * 1987-08-07 1989-02-08 Century Laboratories Inc. Use of free fatty acids for the manufacture of a medicament for treatment of diabetes mellitus
DE19503993A1 (en) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Enteral product contg n-3-fatty acid or deriv and medium chain length tri:glyceride
WO2004082402A1 (en) * 2003-03-18 2004-09-30 Novartis Ag Compositions comprising fatty acids and amino acids
WO2004093869A1 (en) * 2003-04-18 2004-11-04 Zone Enterprises, Inc. Novel dietary compositions to reduce inflammation
WO2005060954A1 (en) * 2003-12-19 2005-07-07 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302481A2 (en) * 1987-08-07 1989-02-08 Century Laboratories Inc. Use of free fatty acids for the manufacture of a medicament for treatment of diabetes mellitus
DE19503993A1 (en) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Enteral product contg n-3-fatty acid or deriv and medium chain length tri:glyceride
WO2004082402A1 (en) * 2003-03-18 2004-09-30 Novartis Ag Compositions comprising fatty acids and amino acids
WO2004093869A1 (en) * 2003-04-18 2004-11-04 Zone Enterprises, Inc. Novel dietary compositions to reduce inflammation
WO2005060954A1 (en) * 2003-12-19 2005-07-07 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DELARUE JACQUES ET AL: "n-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?", REPRODUCTION NUTRITION DEVELOPMENT, vol. 44, no. 3, May 2004 (2004-05-01), pages 289 - 299, XP002365756, ISSN: 0926-5287 *
FASCHING P ET AL: "Metabolic effects of fish-oil supplementation in patients with impaired glucose tolerance.", DIABETES. MAY 1991, vol. 40, no. 5, May 1991 (1991-05-01), pages 583 - 589, XP009060859, ISSN: 0012-1797 *
JENG K C G ET AL: "Sesamin inhibits lipopolysaccharide-induced cytokine production by suppression of p38 mitogen-activated protein kinase and nuclear factor-kappaB", IMMUNOLOGY LETTERS, AMSTERDAM, NL, vol. 97, no. 1, 15 February 2005 (2005-02-15), pages 101 - 106, XP004989642, ISSN: 0165-2478 *
POPP-SNIJDERS C ET AL: "Dietary supplementation of omega-3 polyunsaturated fatty acids improves insulin sensitivity in non-insulin-dependent diabetes.", DIABETES RESEARCH (EDINBURGH, LOTHIAN) MAR 1987, vol. 4, no. 3, March 1987 (1987-03-01), pages 141 - 147, XP009061054, ISSN: 0265-5985 *
SZAPARY P O ET AL: "The triglyceride-high-density lipoprotein axis: An important target of therapy?", AMERICAN HEART JOURNAL, MOSBY- YEAR BOOK INC., ST. LOUIS, MO, US, vol. 148, no. 2, August 2004 (2004-08-01), pages 211 - 221, XP004528114, ISSN: 0002-8703 *
YAM D ET AL: "Omega-3 fatty acids reduce hyperlipidaemia, hyperinsulinaemia and hypertension in cardiovascular patients", JOURNAL OF CLINICAL AND BASIC CARDIOLOGY 2002 AUSTRIA, vol. 5, no. 3, 2002, pages 229 - 231, XP009059911, ISSN: 1561-2775 *
YAM D ET AL: "The effect of omega-3 fatty acids on risk factors for cardiovascular diseases", HAREFUAH 2001 ISRAEL, vol. 140, no. 12, 2001, pages 1156 - 1158+1230, XP009060862, ISSN: 0017-7768 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066915B2 (en) 2006-10-03 2015-06-30 Michael D. Myers Meal replacement compositions and weight control method
US9138415B2 (en) 2009-04-29 2015-09-22 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9585856B2 (en) 2009-04-29 2017-03-07 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Also Published As

Publication number Publication date
WO2006017627A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
WO2006017627A3 (en) Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
NO20063328L (en) Use of a fatty acid composition comprising at least one of EPA and DHA or combinations thereof
JP2021051749A (en) Optimized nutritional formulations, methods for selecting tailored diets therefrom, and using methods thereof
Huang et al. Suppression of acute ethanol-induced hepatic steatosis by docosahexaenoic acid is associated with downregulation of stearoyl-CoA desaturase 1 and inflammatory cytokines
WO2008147562A3 (en) Dietary formulations and methods for treatment of inflammation and other disorders
GB2459809A (en) Fatty acid formulations and methods of use thereof
WO2004004599A3 (en) Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
WO2003063793A3 (en) Fatty acid-containing compositions and methods for the treatment of cytokine mediated disorders
CN103458893B (en) Sn 1 (3) monoacylglycerol ester and lipid absorb
TW200744463A (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
WO2009013596A3 (en) Fortification of nutritional products with olive extracts containing hydroxytyrosol and hydroxytyrosol fortified nutritional products
WO2004112776A3 (en) Inflammatory disease treatment
EP2636404A3 (en) Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products
NZ599748A (en) Improving memory in subjects with mini-mental state examination of 24-26
WO2011097273A8 (en) Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine
ZA200909227B (en) Food composition for prodromal dementia patients
WO2007092509A3 (en) Dietary supplement composition for blood lipid health
MX2009001156A (en) Vitamin d compositions and method of administration to a human being.
DE602007010018D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING CORDYCEPIN FOR THE TREATMENT AND PREVENTION OF FAT
ATE538666T1 (en) DIETARY SUPPLEMENT TO PREVENT WEIGHT LOSS
EP2241196A3 (en) Nutritional supplement comprising oligosaccharides and cysteine for treating hiv
WO2009065395A3 (en) Novel use of omega-3-fatty acid(s)
CY1108138T1 (en) USE OF LUPINOCONGLUTINE FOR TREATMENT OF DIABETES TYPE II
EG25067A (en) Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals.
WO2006016363A3 (en) Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05782593

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05782593

Country of ref document: EP

Kind code of ref document: A2